The new facility will serve the JV’s development of potential cancer drugs
TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that its recently established joint venture ("JV"), MitoCareX Bio, launched its new dedicated, advanced facility for the discovery and development of anti-cancer drug candidates. The new state-of-the-art laboratory and research facility is based in Ness-Ziona Science Park in Israel.
Read more at globenewswire.com